Rationale for the development of recombinant human CC10 as a therapeutic for inflammatory and fibrotic disease.
CC10/uteroglobin is a remarkable protein whose physiological roles have only recently been explored in vivo. Both transgenic mice that have been rendered deficient and humans that have been characterized as deficient in this protein exhibit tendencies toward inflammatory, fibrotic, and oncologic disease, demonstrating the potential of the protein as a therapeutic agent. The protein itself is an excellent candidate for clinical development because of its inherent physical properties. It is relatively small, resistant to proteases, stable to extremes of heat and pH, and can be produced by recombinant methods. The physiological roles of this multifunctional protein continue to be uncovered as research progresses in vitro, in animals, and eventually in humans. The pathways through which CC10 mediates its effects, its receptors, and other family members will be a rich source of exciting research, as well as potential diagnostic and therapeutic agents. This paper is an introductory, noncomprehensive review of some of the scientific and medical rationale in support of CC10-based therapies in selected clinical applications.
Pilon
A L
AL
Claragen, Incorporated, 387 Technology Drive, College Park, MD 20742, USA. apilon@claragen.com
D000208:Acute Disease / Q000628:therapy; D058186:Acute Kidney Injury / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D002908:Chronic Disease / Q000628:therapy; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D009369:Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D011014:Pneumonia / Q000188:drug therapy*; D011506:Proteins / Q000627:therapeutic use*; D011658:Pulmonary Fibrosis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D014598:Uteroglobin
D011506:Proteins; D011994:Recombinant Proteins; C556389:SCGB1A1 protein, human; C556390:Scgb1a1 protein, mouse; D014598:Uteroglobin